Figure 5
CrebA acts downstream of Jra/dJun and its function is required in both muscles and fat body. (a) CrebA acts downstream of Jra/djun. CrebA and CrebA targets expression levels was measured by RT-qPCR on Tubulin > GeneSwith/+; UAS-dJun RNAi/+ individuals induced or not using RU486 at 20 μg/ml. Black bars represent mean value of log2 (fold change) observed in Jra/dJun RNAi mediated knockdown (induced condition) normalized to non-induced condition. P value was calculated using the T-Test method (***P < 0.001; CrebA: P = 2.29e−5; CG5881: P = 6.63e−5; Sec. 61beta: P = 1.79e−4; Spase: P = 4.89e−4; TRAM: P = 2.03e−4). (b–e) Impact of muscle-specific or fat body specific loss of function of CrebA expression on survival of SH and DH flies. Sterile wounding and/or Pe infection were performed on 1 week old adult females of MHC > GeneSwith/+; UAS-CrebA RNAi/+ (CrebA RNAi-1 (muscle)) (b,c) and Lsp2 > GeneSwith/+; UAS-CrebA RNAi/+ (CrebA RNAi-1 (fat body)) (d,e) genotypes in the absence (b,d: not induced) or in the presence (c, e: induced) of RU486 at indicated concentrations. Fly survival was observed up to 50 hours after treatment. (b,c) Muscle-specific CrebA inhibition worsened the survival of SH flies but did not impact that of DH ones. (d,e): Fat body-specific CrebA inhibition worsened SH flies survival. Each group consisted of 120 flies observed among 2 different experiments (60 flies/group/experiment). Statistical analyses were performed using the Log Rank test method (*P < 0.05; ***P < 0.001). Means of survival are shown, and error bars represent standard deviations.
